Interferon alpha-2a and dacarbazine in melanoma.
Department of Medicine, Pittsburgh Cancer Institute, PA 15213.
J M
JM
Kirkwood
M S
MS
Ernstoff
A
A
Giuliano
R
R
Gams
W A
WA
Robinson
J
J
Costanzi
P
P
Pouillart
J
J
Speyer
M
M
Grimm
R
R
Spiegel
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008545:Melanoma / Q000628:therapy*; D011897:Random Allocation; D011994:Recombinant Proteins
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003606:Dacarbazine